Remodeling the immune microenvironment: Engineering IL-2 variants to overcome clinical bottlenecks in PD-1 inhibitor...

Area of Science:

• Oncology
• Immunotherapy
• Cancer Immunology

Background:

• Perioperative chemotherapy combined with PD-1 inhibitors has shown efficacy in gastric cancer, improving event-free survival (EFS).
• However, this combination frequently fails to translate into significant improvements in overall survival (OS), posing a clinical challenge.
• The inadequacy is linked to incomplete remodeling of the immunosuppressive tumor microenvironment and insufficient induction of long-term protective memory T cells.

Purpose of the Study:

• To systematically review the reasons behind the discrepancy between improved EFS and insufficient OS in gastric cancer patients treated with perioperative chemotherapy and PD-1 inhibitors.
• To explore the role of the immune microenvironment in this context.
• To highlight the potential of novel immunotherapeutic strategies, specifically PD-1/IL-2 bispecific antibodies.

Main Methods:

• Systematic review of existing literature.
• Analysis of the tumor immune microenvironment.
• Focus on the mechanisms of action of PD-1/IL-2 bispecific antibodies.

Main Results:

• The immunosuppressive tumor microenvironment is not fully remodeled by current regimens.
• There is a failure to induce stem cell-like memory T cells crucial for long-term immunity.
• PD-1/IL-2 bispecific antibodies are emerging as a promising therapeutic strategy.

Conclusions:

• PD-1/IL-2 bispecific antibodies offer a potential breakthrough by synergizing with existing treatments.
• These antibodies can induce profound immune reprogramming, including expansion of tumor-specific T cells, reversal of T cell exhaustion, and promotion of memory differentiation.
• This approach may invert the balance of effector and suppressor cells, potentially enhancing long-term survival outcomes in gastric cancer.